Suggestions
Nenad Tomasevic
CEO and founder Dren Bio
Nenad Tomasevic is a biotechnology entrepreneur and scientist with extensive experience in the pharmaceutical industry. Here are key details about his background and career:
Education and Early Career
Nenad Tomasevic received his undergraduate, graduate, and doctorate degrees from the University of Belgrade, specializing in protein chemistry.1 He completed his postdoctoral training at the National Institutes of Health (NIDDK, Genetics and Biochemistry Branch) in Bethesda, Maryland.2
Career Highlights
Allakos Inc.:
- Co-founder of Allakos Inc. in 2012
- Served as Vice President of Research from 2012 to 201512
- Identified the original opportunity for developing therapeutic antibodies against Siglec-8
- Responsible for all research and nonclinical development functions2
Previous Positions:
- Held positions at KaloBios and Nuvelo, focusing on therapeutic antibody development
- Began his career at Cytokinetics after completing his postdoctoral training2
Dren Bio:
- Co-founded Dren Bio as CEO in May 2019
- Currently serves on the board of directors2
Expertise and Contributions
Nenad Tomasevic has extensive experience in:
- Protein biochemistry
- Therapeutic antibody development
- Preclinical research and development
- Leadership in biotechnology startups
His work has contributed to the development of novel antibody-based therapeutics for allergic and inflammatory diseases.3
Current Focus
As of 2023, Tomasevic continues to lead Dren Bio as its CEO, focusing on expanding the company's pipeline and identifying optimal clinical applications for their drug candidates.4
Highlights
I am proud to announce that Dren Bio has entered into a collaboration agreement with Novartis to utilize our Targeted Myeloid Engager and Phagocytosis platform for developing novel bispecific antibodies for the treatment of cancer. This new strategic collaboration with Novartis underscores the immense potential of Dren’s innovative platform for harnessing the power of myeloid cells to promote durable immune responses against tumors, potentially opening new avenues for cancer therapy. A heartfelt congratulations to the entire Dren team for their exceptional efforts and scientific rigor as they continue to advance and expand the breadth of our platform. We are excited to embark on this new journey together with Novartis!
We are excited that Amit Mehta is joining Dren’s team to help us expand our pipeline and identify optimal clinical applications for the drug candidates currently in development.
Amit’s scientific, pharmaceutical and business expertise combined with his positive energy and creativity is going to be very visible at Dren.
